Severe acute respiratory syndrome coronavirus 2 non-spike proteins (SARS-CoV-2 non-spike proteins)

SARS-CoV-2 non-spike proteins refer to the collective set of proteins encoded by the viral genome excluding the Surface Glycoprotein (Spike). This group includes 16 non-structural proteins (NSP1-16) that facilitate viral replication and transcription, as well as structural proteins like the Nucleocapsid (N), Membrane (M), and Envelope (E) proteins (V'kovski et al., Nat Rev Microbiol 2021). Key therapeutic targets within this group include the Main Protease (Mpro/NSP5), which is essential for processing the viral polyprotein, and the RNA-dependent RNA polymerase (RdRp/NSP12), which is responsible for synthesizing viral RNA (Hillen et al., Nature 2020). Unlike the Spike protein, which frequently mutates to evade neutralizing antibodies, non-spike proteins like NSP5 and NSP12 are highly conserved across variants, making them ideal targets for small-molecule antivirals. Drugs such as Nirmatrelvir inhibit Mpro to prevent viral maturation, while Remdesivir and Molnupiravir target the RdRp complex to disrupt the replication of the viral genome (Owen et al., Science 2021; Jayk Bernal et al., NEJM 2022). Additionally, proteins like NSP1 and various accessory proteins play critical roles in suppressing the host's innate immune response, further contributing to the pathogenesis of COVID-19.

Other names

SARS-CoV-2 non-structural proteinsSARS-CoV-2 structural proteins (excluding Spike)SARS-CoV-2 accessory proteinsSARS-CoV-2 proteome (non-S)NSPs 1-16Nucleocapsid proteinMembrane proteinEnvelope protein

Inhibition of viral polyprotein cleavage by targeting the main protease (Mpro/NSP5) or papain-like protease (PLpro/NSP3); termination of viral RNA chain elongation by targeting the RNA-dependent RNA polymerase (RdRp/NSP12); and induction of lethal mutagenesis through nucleoside analogs.